HEMATOLOGY

Clinical researchers Dennis Slamon, MD, PhD, and Brian Druker, MD, were recently honored with the 2019 Sjöberg Prize for their ground-breaking contributions toward targeted therapy for patients with breast cancer and chronic myeloid leukemia, respectively.

Lead iLLUMINATE study author Carol Moreno, MD, PhD, discusses the safety and efficacy results from the iLLUMINATE trial which led to the FDA approval of ibrutinib plus obinutuzumab in CLL.

Eunice Wang, MD, discusses the new treatment era for patients with acute myeloid leukemia after the approval of 3 new treatment regimens at the end of 2018.

The first treatment regimen has been approved by the FDA to treat adult patients with acquired thrombocytic thrombocytopenic purpura: the nanobody caplacizumab-yhdp when given in combination with plasma exchange and immunosuppression.

Targeted agents are routinely used to treat many cancers and have improved outcomes for patients with solid tumors and hematological malignancies alike. Recently, targeted therapies made their way into the armamentarium for acute myeloid leukemia, representing the first therapeutic advances for AML in decades.

Matthew S. Davids, MD, MMSc, discusses findings from an updated analysis of the phase III DUO study in patients with CLL.

A look back at all the FDA news in oncology from the month of January 2019, including several new approvals, breakthrough therapy designations, and a partial clinical hold.

In an interview with <em>Targeted Oncology</em>, Ian W. Flinn, MD, PhD, discussed the potential impact of duvelisib&nbsp;on patients with CLL. Flinn serves as the lead investigator of the DYNAMO and DUO studies in duvelisib.

Treating An Elderly Woman with Chronic Lymphocytic Leukemia

The combination of ibrutinib and obinutuzumab has gained FDA approval for the first-line treatment of patients with&nbsp;chronic lymphocytic leukemia or small lymphocytic lymphoma, based&nbsp;on data from the phase III iLLUMINATE trial.

General Cancer

Elizabeth L. Budde, MD, PhD, discusses the interim efficacy results form the phase I study of mosunetuzumab in patients with lymphomas.